ArticleFrontiers in cellular and infection microbiology2025
Seroprevalence of Zika virus and dengue virus infections in migrants in Italy.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Estimating the burden of Zika virus (ZIKV) and dengue virus (DENV) infections in migrants is important to promote their health status and recommend appropriate interventions. We aimed to estimate the seroprevalence of ZIKV and DENV in migrants from high endemic countries attended at a referral center in Rome (Italy), arriving via the Mediterranean from North and sub-Saharan Africa and South-East Asia. Methods: Sixty-four serum samples from migrants were tested for anti-ZIKV and anti-DENV immunoglobulin (Ig) G and IgM by ELISA. Serum samples with detectable Ig were analyzed by indirect immunofluorescence assay (IFA). For confirmatory testing and given the cross-reactivity of antibodies between orthoflaviviruses, all positive IFA sera were tested by virus neutralization test. ZIKV and DENV RNA were assessed by RT Real-Time PCR. Results: All serum samples were negative for anti-ZIKV IgG, while 12.50% (n=8/64) were positive for anti-ZIKV IgM by ELISA. IFA showed that only 1 of 8 serum samples (12.50%) was positive for anti-ZIKV IgM, but ZIKV RNA was undetectable. The seroprevalence of anti-DENV IgG by ELISA was 59.37% (n=38/64), mostly confirmed by IFA (97.36%, n=37/38). Furthermore, anti-DENV IgM were detected in 9 serum samples (n=9/64, 14.06%) by ELISA, previously tested negative for anti-DENV IgG. Of these, 2 sera were confirmed by IFA, but DENV RNA was not detectable. Anti-DENV neutralizing antibodies (nAbs) were detected in 27% of anti-DENV IgG sera (n=10/37) tested by IFA. Multiple linear regression analysis showed that sub-Saharan African origin was an independent factor for the development of anti-DENV nAbs (p=0.009), while age and gender had no effect. Sera negatives for anti-DENV nAbs but with detectable anti-DENV IgG tested by IFA had nAbs to another orthoflavivirus (n=25/27, 92.59%) such as West Nile virus (WNV) (n=17/25, 68%), Yellow fever virus (YFV) (n=7/25, 28%) and Usutu virus (USUV) (n=1/25, 4%). Discussion: A high prevalence of anti-orthoflavivirus IgG, especially against DENV, was found in the migrant population studied, but no infections were detected. With the recent outbreaks of autochthonous DENV infections in Italy, the risk of secondary DENV infection - and severe disease - could be high. Robust serological surveillance, vaccination and prevention strategies for this vulnerable group are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.